PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Bristol Myers Squibb opens 125-acre biologics campus in Dublin

The facility also includes a cell culture suite, quality control laboratories, and technology labs.

Bristol Myers Squibb has officially opened its Cruiserath Biologics site in Dublin. The site, which represents a $1bn investment – was officially opened by the company’s chief executive officer, Giovanni Caforio, who arrived from New York, and site general manager Pádraig Keane.

The facility is over 125 acres in size and received US Food and Drug Administration (FDA) approval in 2019, European Medicines Authority (EMA) site approval the following year and is now in commercial manufacture.

Employing over 450 people on campus, Cruiserath has the manufacturing capacity necessary to meet the growing demand for existing biologics products, as well as anticipated requirements for products currently within the Bristol Myers Squibb pipeline.

It also includes a cell culture suite, quality control laboratories, and technology labs as well as a cryogenics logistics facility. All the ventures will support ongoing commercial testing, development, and manufacturing.

Padraig Keane explained: “It is a proud day at Cruiserath Biologics as we celebrate the opening of our site with the presence of our global leadership team. Biologics manufacturing is a highly complex, sensitive process, truly unique – from the manufacture, to package, storage, and transit to reach our patients.”

“This requires a commitment from each employee, across every department as well as collaboration across our network. Our people are truly committed to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases,” he added.

Karin Shanahan, who leads the company’s global manufacturing network, commented: “The Cruiserath Biologics site will play a crucial role in our company’s success moving forward. Coupled with the breadth of knowledge and expertise of our employees, this multi-product site will allow us to further enhance our operations as we strive to get more medicines to more patients faster.”

Having opened its doors with a pharmaceutical ingredient plant in County Dublin in 1964, Bristol Myers Squibb became one of the first pharmaceutical companies in Ireland.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026